PARP Inhibitor Market, By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

PARP Inhibitor Market was valued at US$ 12.5 billion in 2024 and is projected to grow at a CAGR of 18.3% to reach US$ 67.0 billion by 2034.

As cancer turns aggressive in nature, it is prone to attack other parts of the body. An increase in the number of aggressive cancer cases has poised cancer treatment as a challenge for the healthcare industry.  Variety of cancer treatment methods are being employed, such as surgery, chemotherapy, PARP inhibitor and radiation therapy. PARP inhibitors are used to treat many heritable cancers. These inhibitors depend on PARP cells rather than regular cells and are attractive target for cancer therapy. Chemotherapy and radiation therapy attempt to kill cancer cells by inducing high levels of DNA damage. By inhibiting PARP1 DNA repair, the effectiveness of these therapies can be increased. BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for one of these proteins is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells. PARP1 is a protein that is important for repairing single-strand breaks.

Impact of Covid-19 pandemic on market

Number of patients suffering from cancer is rising day by day. Due to closing of research labs and a break in the supply chain, the market of PARP inhibitor has suffered a setback. This report will quantify the impact of this pandemic on the market.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Rising prevalence of cancer patients

The National Cancer Institute reports that more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world’s cancer deaths also occur in these regions. The International Agency for Research on Cancer (IARC) predicts that by 2030, the global burden is expected to rise to 21.7 million new cancer cases and 13 million cancer deaths, simply due to growth and aging of population, leaving aside factors, such as smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries which boost the market of PARP inhibitor.

High demand for PARP inhibitor for ovarian cancer

Ovarian cancer held a major market position for PARP inhibitors which boost the market. PARP inhibitors have ability to help repair damaged DNA and hence becoming increasingly useful tool for various treatments for cancers which drives the market. Several PARP inhibitors are in last-stage pipeline, thus creating positive growth factors for this market.

However, technical and clinical-related challenges might hamper growth of the global market to a certain extent.

The PARP inhibitor market is segmented based on drug, indication, distribution channel, and region.

On the basis of drug, the global PARP inhibitor market is segmented into lynparza, niraparib, rucaparib and others. Based on indication, the target market is segmented into ovarian cancer, breast cancer, prostate cancer, lung cancer and others. On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.

Regional Insights:

On region, the PARP inhibitor market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the market of PARP inhibitor market due to increasing aging population and prevalence of large number of diseases. Further, presence of key players and advancement in technologies are the driving factor for this region.

Report Scope:

Attribute	Details
Market Size 2024	US$ 12.5 billion
Projected Market Size 2034	US$ 67.0 billion
CAGR Growth Rate	18.30%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Drug- Lynparza, Niraparib, Rucaparib and Others. By Indication– Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and others. By Distribution Channel– Hospital pharmacies, Online pharmacies and Others.
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the PARP Inhibitor Market report based on Drud, indication, distribution channel and region:

PARP inhibitor market, By Region:

• North America
  • Rest of Middle East & Africa
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the PARP inhibitor market includes AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Jiangsu Hengrui Medicine Co., Ltd, Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc. Companies are continuously rising the production and supply of drugs to grow this market.

• Genentech, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca Plc.
•  Johnson & Johnson
•  GlaxoSmithKline plc.
•  Pfizer Inc.
•  Jiangsu Hengrui Medicine Co. Ltd
•  Clovis Oncology Inc.
•  AbbVie Inc.
• Bristol - Myers Squibb
• Merck KGaA

 “*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for PARP Inhibitor Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Drug
     • Market Snippet, By Indication
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Market Segmentation, By Drug, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Lynparza
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Niraparib
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Rucaparib
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Other
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
6. Market Segmentation, By Indication, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Ovarian cancer
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Breast cancer
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Prostate cancer
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Lung cancer
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Others
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
7. Market Segmentation, By Distribution channel, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Hospital pharmacies
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Online pharmacies
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Others
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
8. Global Market, By Region, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • Brazil
       • Mexico
       • Rest of Latin America
   • Middle East & Africa
     • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Indication, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • GCC
       • Israel
       • South Africa
       • Rest of Middle East
9. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
10. Company Profiles

• Genentech, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca Plc.
•  Johnson & Johnson
•  GlaxoSmithKline plc.
•  Pfizer Inc.
•  Jiangsu Hengrui Medicine Co. Ltd
•  Clovis Oncology Inc.
•  AbbVie Inc.
• Bristol - Myers Squibb
• Merck KGaA

The Last Word

• Future Impact
• About Us
• Contact